• Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors

    • December 17, 2018
    • Posted By : admin
    • 0 Comment
    •   108 views

    Eli Lilly and Company (NYSE: LLY) and Evidation Health, a health and measurement company that helps innovative life sciences and health care companies understand how everyday behavior and health interact, announced today that they have expanded their collaboration with a multi-year agreement to provide Lilly with global access to Evidation’s Andromeda data platform.

    As a result of this announcement, Lilly scientists and researchers across therapeutic portfolios will have access to Evidation’s data platform with the goal of uncovering new ways to measure and understand a patient’s health by accessing consented data derived from smartphones, connected sensors, wearables, and even his or her own voice. The terms of the agreement are undisclosed.

    “Digital health advancements, including mobile devices and wearables, have the potential to improve and personalize health outcomes,” said Divakar Ramakrishnan, Lilly’s Chief Digital Officer. “By leveraging Evidation’s Andromeda platform, Lilly’s scientists are gaining a deeper understanding of the physiological, environmental, and contextual indicators that can help shape future advancements in medicine and medicine delivery.”

    With Andromeda, Lilly scientists now have instant access to a private, collaborative, and secure analytical environment where they can use powerful, Evidation-built algorithms to process raw data for use in clinical studies or to create their own predictive models. The models turn complex, patient-generated behavior data into novel, quantifiable, and clinically meaningful insights that can transform how diseases are identified, treated, and monitored.

    As one example among multiple therapeutic areas, Evidation’s data platform is being used by Lilly to analyze data from continuous glucose monitors, insulin pumps, and real world information to improve the experience of people with diabetes and support the company’s significant efforts to build a connected ecosystem that includes an automated insulin delivery device and connected insulin pen.

  108 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!